Insulin R/CD220 Protein, Human (HEK293, His)

The insulin R/CD220 protein is a receptor tyrosine kinase that coordinates insulin action by phosphorylating substrates such as IRS and SHC upon insulin binding. Phosphorylated IRS activates PI3K-AKT/PKB to exert metabolic effects, and activates Ras-MAPK to promote growth and differentiation. Insulin R/CD220 Protein, Human (HEK293, His) is the recombinant human-derived Insulin R/CD220 protein, expressed by HEK293 , with C-10*His labeled tag.

The Insulin R/CD220 protein, a receptor tyrosine kinase, orchestrates the diverse actions of insulin through the phosphorylation of multiple intracellular substrates upon insulin binding. These substrates include insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL, and other signaling intermediates. Phosphorylated IRS proteins activate two main signaling pathways: the PI3K-AKT/PKB pathway, pivotal for insulin's metabolic effects, and the Ras-MAPK pathway, which collaborates with PI3K to regulate cell growth and differentiation. The PI3K-AKT/PKB pathway triggers the translocation of the glucose transporter SLC2A4/GLUT4 to the cell membrane, facilitating glucose transport. Activated AKT/PKB, a downstream effector, induces an anti-apoptotic effect by phosphorylating BAD, regulates the expression of metabolic enzymes, and modulates the mTORC1 signaling pathway, integrating insulin signals for cell growth and metabolism. The Ras/RAF/MAP2K/MAPK pathway mediates insulin-induced cell growth, survival, and cellular differentiation. In addition to insulin, the receptor can bind insulin-like growth factors (IGFI and IGFII). Hybrid receptors composed of IGF1R and INSR isoforms exhibit varying affinities for IGFs and insulin, influencing their activation patterns. Furthermore, in adipocytes, the receptor inhibits lipolysis.

Measured by its binding ability in a functional ELISA. When 15 ng/mL of biotinylated recombinant human Insulin is added to serially diluted Recombinant Human Insulin R/CD220, the concentration of Recombinant Human Insulin R/CD220 that produces 50% of the optimal binding response is ≤730.7 ng/mL.

Human

HEK293

C-10*His

P06213-1 (H28-K956)

3643

Partial

HLYPGEVCPGMDIRNNLTRLHELENCSVIEGHLQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYALVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNEECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECLGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQGCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGCTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETLEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQERNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFSDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWERQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQILKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAFPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYVSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCVSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAK

Approximately 37-48 kDa (β subunit) & 100-130 kDa (α subunit), based on SDS-PAGE under reducing conditions, due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.